What is the global market size of Mycoplasma Testing Market?

Mycoplasma Testing Market size was valued at USD 262.2 Million in 2021 and is poised to grow from USD 298.91 Million in 2022 to USD 852.66 Million by 2030, at a CAGR of 14% during the forecast period (2023-2030).

What is the key driver of Global Mycoplasma Testing Market?

The growing demand for biopharmaceuticals and cell-based therapies is driving the Mycoplasma testing market. These products and therapies require high-quality cells that are free from Mycoplasma contamination to ensure their safety and efficacy.

What is the key market trend for Global Mycoplasma Testing Market?

Development of advanced testing technologies and platforms: The Mycoplasma testing market is witnessing the development of advanced technologies and platforms, such as PCR-based assays, nucleic acid sequencing, and flow cytometry, that offer higher sensitivity, specificity, and speed compared to traditional culture-based methods.

Which region accounted for the largest share in Global Mycoplasma Testing Market?

In 2022, North America dominated the market and accounted for a revenue share of 40.0%. Due to the well-established healthcare sector in this business and the increased prevalence of respiratory illnesses, market share growth is predicted. The existence of multinational pharmaceutical and biotech corporations in the area, as well as increased investment in R&D operations, are other factors contributing to the growth of this region.

Top Mycoplasma Testing Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Mycoplasma Testing Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Mycoplasma Testing industry players.

Mycoplasma Testing Market Competitive Landscape

The nature of the global mycoplasma testing market is highly competitive owing to the presence of several established players and new entrants. The market players are focusing on developing advanced technologies and solutions, expanding their product portfolios, and establishing strategic partnerships and collaborations to strengthen their position in the market. The Mycoplasma testing market is expected to continue to grow and evolve, driven by technological advancements, increasing demand for biopharmaceuticals and cell-based therapies, and stringent regulatory requirements. The market players are likely to continue to invest in R&D and innovation to develop more efficient, accurate, and cost-effective testing solutions to meet the growing demand from customers.

Mycoplasma Testing Market Top Player’s Company Profiles

Merck KGaA (Germany)

Thermo Fisher Scientific Inc. (US)

Lonza Group Ltd. (Switzerland)

Sartorius AG (Germany)

PromoCell GmbH (Germany)

American Type Culture Collection (ATCC) (US)

Agilent Technologies, Inc. (US)

Bionique Testing Laboratories, Inc. (US)

Biological Industries Israel Beit Haemek Ltd. (Israel)

Charles River Laboratories International, Inc. (US)

Creative Bioarray (US)

InvivoGen (US)

Minerva Biolabs GmbH (Germany)

Biological Industries US, Inc. (US)

Norgen Biotek Corp. (Canada)

Novacyt Group (UK)

Mycoplasma Experience (France)

Genscript Biotech Corporation (China)

GeneCopoeia, Inc. (US)

Jena Bioscience GmbH (Germany)

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

Global Mycoplasma Testing Market size was valued at USD 897.33 Million in 2024 and is poised to grow from USD 967.32 Million in 2025 to USD 1764.09 Million by 2033, growing at a CAGR of 7.8% during the forecast period (2026–2033).

Established and emerging companies compete with each other in the mycoplasma testing industry, introducing competition. Companies often depend on strategic alliances and innovative testing methods to firmly position themselves within the market. Regional companies are also becoming more aggressive as they expand their ranges to suit local customers. 'Thermo Fisher Scientific Inc. (USA)', 'Merck KGaA (Germany) ', 'Lonza Group Ltd. (Switzerland) ', 'Charles River Laboratories International Inc. (USA) ', 'Eurofins Scientific SE (Luxembourg) ', 'Roche Diagnostics (Switzerland) ', 'Agilent Technologies Inc. (USA) ', 'Bio-Rad Laboratories Inc. (USA) ', 'Sartorius AG (Germany) ', 'bioMerieux SA (France) ', 'Asahi Kasei Corporation (Japan) ', 'American Type Culture Collection (ATCC) (USA) ', 'Bionique Testing Laboratories Inc. (USA) ', 'InvivoGen (USA) ', 'PromoCell GmbH (Germany) ', 'Biological Industries Israel Beit Haemek Ltd. (Israel) ', 'Creative Bioarray (USA) ', 'Mycoplasma Experience (UK) ', 'Norgen Biotek Corp. (Canada) ', 'Biotools B & M Labs S.A. (Spain)'

Demand for mycoplasma testing is increasing, driven by an upsurge in the research and development of biological products in biotechnology and pharmaceuticals, including cell-based medicines and vaccines. As more and more researchers increasingly rely on cell lines for manufacturing, the requirement for a mycoplasma infection-free cell line stream has become necessary. As businesses grow through giving increased priority to quality assurance during their research operations, mycoplasma testing market demand is rising along with the need for rigorous testing methodologies.

Integration of Automation in Testing: Automation in the operations of laboratories and testing operations such as mycoplasma testing is now quite a routine affair. Automated systems ensure reduction of testing time to a level that is significantly lower, productivity increases sharply, and human errors are considerably minimized. The expanding interest of biopharmaceutical companies in enhancing process efficiency with uniform quality will keep on boosting their demand for mycoplasma testing technology companies.

According to the global mycoplasma testing market forecast, North America led the market in 2023 with a revenue share of 39.04%. A combination of several factors leads to a high mycoplasma testing market share. Prevalence of respiratory disorders is also at a high level and the rising investment in biotechnology by major companies since its wide application in cancer research and developing novel biologics, vaccines, and drugs. Besides, through the development and integration of strict regulatory requirements, companies such as the FDA and the U.S. Department of Health and Human Services, in collaboration with the Centers for Disease Control and Prevention and the National Institutes of Health, continually advance standards on the testing of biological and microbiological safety of biomedical laboratories.

Top Mycoplasma Testing Companies

Mycoplasma Testing Market Competitive Landscape

FAQs

What is the global market size of Mycoplasma Testing Market?

Who are the key vendors in the Mycoplasma Testing Market?

What is the key driver of Mycoplasma Testing Market?

What is the key market trend for Mycoplasma Testing Market?

Which region accounted for the largest share in Mycoplasma Testing Market?

Request Free Customization